Galena Biopharma, Inc. (NASDAQ:GALE) closed its last session at $0.4554 with the change of -11.5041%. The market capitalization of the company is $82.81M with an average Volume of 6.61 million shares. The stock currently has its 52-Week High range of $2.4900 and 52-week low range of $0.2800. The Price to Book (P/B) ratio stands at 7.5676. The stock traded total quantity of 20.64 million shares.
For the current Fiscal Quarter, 4 analysts have given an average earnings per share forecast of $-0.07. The Low Earnings per share estimate of the current Quarter is $-0.09 and High Estimate is set at $-0.05 according to these Analysts opinions. The Previous Year EPS of this Quarter is $-0.1.
The Company currently has Highest Price Target of $5 and Lowest Price Target of $0.4. It has Median Price Targets of $4. Mean price target is set at $3.13 after consensus analysis of 3 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 1 analysts have assigned this stock as Strong Buy where 4 assigned Buy, 0 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.b
Organovo Holdings, Inc. (NYSEMKT:ONVO) ended its last trade at $3.88 with the move of -1.52%. The company has market value of $358.48M with the total traded volume of 1.55 million. The stock currently has its 52-Week top value of $4.35 and 52-week down value of $1.60. The price to book (P/B) ratio of the company is 5.85. Its previous closing price was recorded at $3.94.
For the current Fiscal Quarter, 2 analysts have given an Average earnings estimate of $-0.1 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-0.11 while High Estimate is $-0.09. The Previous Year EPS of this Quarter is $-0.1.
According to 2 analysts, an Average Revenue Estimate of the current Fiscal quarter is $530.00K. According to them, the Low Revenue estimate is $300.00K and High Revenue estimate is $750.00K.
The Company currently has High Price Target of $4. The Low and Mean Price Targets are $4 and $4 respectively. These price targets are set after consensus analysis of 2 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 1 analysts have given this stock as Strong Buy where 1 issued Buy, 0 analysts think that it’s a Hold, 0 told Underperform and0 assigned Sell rating.